CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
LY2940680 Capsule(s) (Reference) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01681186
NCT01681186Phase 1Completed
CompareCT.gov

A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Sep 7, 2012·Updated Oct 21, 2019

In Brief

A Phase 1 clinical trial evaluating LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), and 2 other interventions for Healthy Participants. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants. Part A will involve two groups of participants, each taking up to two single doses of LY2940680 at different dose levels. There is a minimum 14 day washout period between each of the participant's doses. The purpose of Part B is to study how much of the study drug, in capsule or tablet form, gets into the bloodstream and how long the body takes to get rid of it. In addition, the effect of food and a proton pump inhibitor (PPI) on LY2940680 will be studied. Part B will involve one group of participants who will take four single doses of 100 milligrams (mg) LY2940680. There is a minimum 7 day washout period between doses. Participants may only enroll in one part. Screening is required within 28 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 7, 2012
Enrollment StartSep 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.8 years ago

Interventions

LY2940680 Capsule(s) (Reference)drug

Administered orally as a capsule(s)

LY2940680 Tablet (Test)drug

Administered orally as a tablet

Lansoprazoledrug

Administered orally as a capsule

Placebo Capsule(s)drug

Administered orally as a capsule(s)